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hampered studies concerning the biological role of PKC in proliferation and differentiation of hematopoietic cells.
We recently showed that primary, human erythroid progenitors have the capacity to undergo up to 20 renewal divisions in vitro in the presence of Epo, SCF and dexamethasone resulting in a 10 6 -fold increase of cell numbers (36) . These erythroid precursors develop to mature erythrocytes during 3-5 cell divisions as soon as the 'renewal factors' Epo, SCF and dexamethasone are replaced by 'differentiation factors' Epo and Insulin. Renewal divisions are characterized by size control (maintenance of a constant cell size) and sustained low levels of hemoglobin. Differentiation divisions are characterized by a loss of size control, resulting in a ~4-fold reduction in cell volume and shortening of the G1-phase of the cell cycle, while cellular hemoglobin increases (37) . Epo is required for both renewal and differentiation divisions, while SCF plus Dex are essential to sustain renewal divisions with no or minimal differentiation (36, 38) . Since PKC was reported to be essential for at least some effects of EpoR-activation and appeared to inhibit SCF-signaling, we set out to further define the role of PKC in erythropoiesis, particularly with respect to regulation of proliferation and differentiation of erythroid cells.
In this paper, we demonstrate that constitutive PKC-activity is essential for phosphorylation and activation of the EpoR and multiple Epo-induced pathways. Our data suggest that PKC may control EpoR function directly or indirectly at the receptor level. In addition, LY294002, a specific inhibitor of phosphatidylinositide 3-kinase (PI3K) also reduced Epo-induced phosphorylation of multiple substrates, which could be partially reversed by activators of PKC.
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Experimental Procedures
Cells and cell culture. Primary erythroid progenitors were grown from human bone marrow as previously described (36) in presence of recombinant human Epo (0.5U/ml, a kind gift from Janssen-Cilag, Tilburg, The Netherlands), recombinant human SCF (100ng/ml, a kind gift from Amgen) and dexamethasone (5x10 -7 M, Sigma). Cells were cultured at 1.5 -3x10 6 /ml through daily dilutions or medium changes with fresh medium containing factors.
Cells were counted on an electronic cell counter (CASY-1, Schärfe-System, Germany). To induce terminal differentiation, cells were washed and transferred to medium with recombinant human Epo (5U/ml), human insulin (1U/ml Actrapid, Bayer-Leverkusen) and a high concentration of iron loaded transferrin (0.7mg/ml).
The murine erythroid cell line LK-I/11 (ED, MvL, HB manuscript submitted) was cultured in StemPro medium (Life Technology) supplemented with Epo (0.5U/ml), SCF (100ng/ml) and dexamethasone (5x10 -7 M). Low molecular weight inhibitors GF109203X, Chelerythrine, CalphostinC, LY294002 and Rapamycin were purchased from Biomol, PMA from Sigma and AG490 was a kind gift of Dr. A. Levitsky (Hebrew University of Jerusalem, Israel). All inhibitors were dissolved in DMSO and diluted at least 500-fold in medium to obtain the final concentrations as indicated in the results.
Determination of hemoglobin accumulation and cell morphology.
To determine hemoglobin accumulation, 3 x 50 µl aliquots of the cultures were removed and processed for photometric determination of hemoglobin (39) . To analyze cell morphology, cells were cytocentrifuged onto slides and stained with histological dyes and neutral benzidine for hemoglobin (40) . Images were taken using a CCD camera and processed with Adobe Photoshop.
Preparation of cell lysates, immunoprecipitation, and Western blotting. Cultured cells were washed once with PBS and incubated in plain Iscove's medium without FCS or growth factors for 4 hours at a density of 4x10 6 /ml. If cells were factor depleted for more than 4 hours, they were incubated in serum free medium containing BSA (1% wt/vol) as previously described (41) . Cells were concentrated to 20 -40 x10 6 /ml, stimulated 10 minutes at 37° C with either 10U/ml rhEpo or 1µg/ml SCF, and 10 volumes of ice-cold phosphatebuffered saline (PBS) supplemented with 10µM Na3VO4 were added. Cells were pelleted and lysed for 30 minutes at 4ºC in lysis buffer (20mM Tris-HCl pH8.0, 137mM NaCl, 10mM EDTA, 100mM NaF, 1% (vol/vol) NonidetP-40, 10% (vol/vol) glycerol, 2mM Na3VO4, 1mM
Pefabloc SC, 50µg/mL aprotinin, 50µg/mL leupeptin, 50µg/mL bacitracin, and 50µg/mL iodoacetamide). Lysates used for JAK2 immunoprecipitation were prepared in a JAK2-buffer (50mM Tris-HCl pH8.0, 200mM NaCl, 0.5% (vol/vol) TritonX-100, 10% (vol/vol) glycerol, by guest on http://www.jbc.org/ Downloaded from 6 2mM Na3VO4, 1mM Pefabloc SC, 50µg/mL aprotinin, 50µg/mL leupeptin, 50µg/mL bacitracin, and 50µg/mL iodoacetamide). Lysates were cleared by centrifugation at 4ºC for 15 minutes at 15,000g. Immunoprecipitations and Western blots were performed as described previously (42) . In some instances, membranes were stripped in 62.5mM Tris-HCl pH6.7, 2% (wt/vol) SDS, and 100mM β-mercaptoethanol at 50°C for 30 minutes, reblocked, washed, and reprobed. Antibodies used were mouse monoclonal antibodies recognizing Grb2, SHP1, SHP2, LYN or SHC (Transduction Laboratories, Lexington, KY) rabbit antisera recognizing JAK2, EpoR or Gab1(Upstate Biotechnology, Lake Placid, NY) rabbit antisera recognizing the mouse EpoR, c-Kit or p44/p42 MAP kinase (Santa Cruz Biotechnology, Santa Cruz, CA) rabbit antisera recognizing Phospho-PKB (Ser473) or PKB, mouse monoclonal antibodies recognizing phospho-p44/p42 MAP kinase (Thr202/Tyr204, New England Biolabs, Beverly, MA) and the anti-phosphotyrosine mouse monoclonal antibody 4G10 (Upstate Biotechnology, Lake Placid, NY). STAT5 antiserum was a kind gift of Dr T.
Decker (University of Vienna, Austria). Subtype specific PKC antibodies and the peptides against which the antibodies were raised were obtained from Gibco (Paisley, Scotland).
Detection of membrane-bound EpoR. Human recombinant Epo was biotinylated using biotin-aminocaproyl-hydrazide as described previously (43) . Cultured cells were washed and incubated in plain Iscove's medium without FCS or growth factors for 4 hours in presence or absence of LY294002 (30µM) or GF109203X (20µM), or incubated in serum free medium with BSA for 12 hours in presence or absence of PMA (50nM). Subsequently cells were stimulated with Epo (5U/ml) or left untreated. The EpoR was detected using biotinylated Epo essentially as previously described (44) . Cells were washed with PBS containing 1% FCS and 0.02% sodium azide and incubated in PBS/FCS/azide plus biotinylated Epo for 1 hour at room temperature in presence or absence of a 100-fold excess unlabeled Epo. Cells were washed, incubated with PhycoErythrin-labeled streptavidin, washed, incubated with biotinlabeled anti-streptavidin, washed, incubated again with PhycoErythrin-labeled streptavidin and washed. Subsequently cells were analyzed by flow cytometry on a FACS. Excess unlabeled Epo fully suppressed the signal obtained with biotinylated Epo, indicating specific detection of the EpoR.
Preparation of nuclear extracts and Electrophoretic mobility shift assay (EMSA).
Nuclear extracts and STAT5 mobility shift assay were performed as described (41) . The oligonucleotide probe used in this study was the β-casein probe (5-AGATTTCTAGGAATTCAATCC; ref. 45) . The DNA-protein complexes were separated by electrophoresis on 5% polyacrylamide gels containing 5% glycerol in 0.25xTBE. The gels were dried analyzed by autoradiography and shifted probe was quantified on the Image Quant Phosphoimager.
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In vitro kinase assay. Sepharose beads with immune complexes were washed twice in lysis buffer and once in kinase buffer (10mM HEPES pH7.4, 50mM NaCl, 5mM MgCl, 5mM
MnCl 2 , 0.5mM DDT) at 4ºC. Beads were resuspended in 100 µl kinase buffer supplemented with protease inhibitors (see above), 1mM ATP (unlabeled) and 10µCi [ DNA-binding in a dose dependent manner ( Figure 1A ). In control incubations the addition of solvent, DMSO, had no effect on Epo-induced STAT5 DNA-binding (data not shown).
Cytological analysis indicated that incubation of the cells with the inhibitors did not induce any apparent cell death.
We then tested the contribution of other pathways to Epo-induced Stat5 phosphorylation.
Firstly, PKC activity is often associated with PI3K activity. Addition of the PI3K-inhibitor LY294002 inhibited Epo-induced STAT5 DNA-binding as well ( Figure 1B) . This was not due to inhibition of TOR-kinases (Target of Rapamycin; 50), as addition of rapamycin had no effect on Epo-induced STAT5 DNA-binding ( Figure 1B) . Secondly, Epo-induced STAT5 phosphorylation was shown to depend on active JAK2 (45) . Addition of the specific JAK2 inhibitor AG490 (51) resulted in concentration dependent inhibition of STAT5 activation to an extent comparable to that induced by the PKC-inhibitors ( Figure 1C ).
PMA (phorbol 12-myristate 13-acetate) is a pleiotropic modulator of PKC activity. PMA activates PKC, but activation is followed by a rapid cleavage and depletion of certain PKC subtypes (29) . We therefore evaluated the Epo-response upon increasing exposure of the cells to PMA. Erythroid progenitors were factor-depleted for 8 hours and subsequently 
PKC-inhibitors do not alter the kinetics of Epo-induced STAT5 activation
We next examined whether the PKC inhibitors altered the time-kinetics of Epo-induced STAT5 activation. Cells were pretreated with 20µM GF109203X or 100nM Gö6976 and Epoinduced STAT5 DNA-binding was analyzed at successive time intervals. In the presence of PKC-inhibitor, the increment of STAT5 DNA-binding was reduced as compared to untreated control cells. In both cases maximal activation was reached at 20 minutes following the onset of Epo-stimulation, indicating an effect on the magnitude rather than on the duration of the response ( Figure 3 ). In addition we examined whether the tyrosine phosphatase inhibitor sodium-orthovanadate (Na 3 VO 4 ) would restore Epo-induced STAT5 activation. While Na 3 VO 4 caused a general increase of DNA-bound STAT5 both in the presence and absence of PKCinhibitors, 10µM Na 3 VO 4 did not relieve suppression of Epo-induced STAT5 by PKCinhibitors (data not shown). Thus, reduction of Epo-induced STAT5 activation following inhibition of PKC does not result from accelerated down-regulation of EpoR signaling.
PKC activity is required for the activation of multiple signal transduction routes initiated upon binding of Epo to its receptor.
Inhibition of PKC could specifically affect Epo-induced STAT5 activation, or it could interfere with signaling from the EpoR in general. Human erythroid progenitors were preincubated with the PKC inhibitor GF109203X (20µM), which suppressed Epo-induced phosphorylation of STAT5, the EpoR and JAK2 in response to Epo ( Figure 4A ). GF109203X had no effects in absence of Epo.
Similar to erythroid progenitors from human bone marrow, murine erythroid progenitors from fetal liver can be expanded in presence of Epo, SCF and Dex. These cells are grown in serum-free medium and are a much more reproducible and clean system for signal transduction studies in erythroid progenitors. Moreover, using p53-/-fetal liver cells indefinite cultures of erythroblasts could be established reproducibly. Like human erythroblasts the cells retain the capacity to differentiate in presence of Epo plus Insulin (ED, MvL, HB manuscript submitted, see Experimental Procedures). In a cloned culture of these mouse erythroid progenitors, LK-I/11, STAT5 was similarly inhibited by PKC-inhibitors (data not shown). To examine which pathways are controlled by PKC and PI3K, the cells were preincubated with the JAK2 inhibitor AG490 (50µM), GF109203X (20µM) or LY294002 (30µM).
All three inhibitors suppressed Epo-induced tyrosine phosphorylation of the EpoR, STAT5
and Gab1 ( Figure 4B and data not shown). Furthermore, the inhibitors suppressed Epoinduced phosphorylation of ERK on Thr202/Tyr204 and Epo-induced tyrosine phosphorylation of several proteins detected in whole cell lysate ( Figure 4B ). Exceptionally, Epo-induced JAK2 phosphorylation was reduced to a lesser extend ( Figure 4B ).
In conclusion, active PKC is required not only for Epo-induced STAT5 DNA-binding, but also for Epo-induced phosphorylation of the EpoR, and downstream targets both in human and mouse erythroid progenitors.
PKC-inhibitors do not affect c-Kit signal transduction while LY294002 shows partial but distinct control of c-Kit function in erythroid progenitors.
Subsequently, we wanted to examine whether other receptors present in the same cells are similarly controlled by PKC. Murine erythroid progenitors were preincubated with increasing concentrations of the PKC-inhibitor Gö6976 and subsequently stimulated with Epo or SCF.
Ligand-induced phosphorylation of ERK1/2 and PKB was analyzed using phospho-specific antibodies on Western blots. Gö6976 inhibited Epo-induced phosphorylation of ERK and PKB, but it did not affect SCF-induced phosphorylation of these proteins ( Figure 5A ).
Similarly, Epo-and SCF-induced phosphorylation of ERK1/2 and PKB was assessed in LK-I/11 cells preincubated with increasing concentrations of the PI3K inhibitor LY294002. At 30µM, LY294002 suppressed phosphorylation of ERK by Epo, while it did not affect SCF-induced ERK phosphorylation ( Figure 5B ). Thus, active PKC and PI3K are required to render the EpoR permissive for ligand-induced signaling, but they do not control c-Kit signaling.
Phosphorylation of PKB by Epo or SCF was completely suppressed at 7.5µM LY294002.
This efficient inhibition of Epo and SCF induced phosphorylation of PKB represents inhibition of Epo-or SCF-induced PI3K activity, as previously documented (10, 13, 14, 53) . Apparently, the LY294002 concentration required to suppress EpoR activity is at least 5-fold higher than that required to inhibit PKB phosphorylation through either the EpoR or c-Kit. This suggests that inhibition of EpoR signaling may require a complete inhibition of all PI3K activity and not only inhibition of class Iα PI3K activated by the EpoR and c-Kit.
Expression of PKC subtypes in erythroid progenitors
Epo-responses were blocked by Gö6976, a specific inhibitor of Ca (Table 1) . This suggests that PKCα may mediate transregulatory control of the EpoR complex.
Inhibition of PKC suppresses mainly erythroid differentiation
While PKC appears to be required for EpoR signaling, it has been shown to attenuate 
PKC neither affects in vitro JAK2 kinase activity or its association with the EpoR.
Inhibitors of PKC and PI3K suppressed Epo-induced tyrosine phosphorylation of the EpoR and JAK2, the earliest events in activation of the EpoR/JAK2 complex ( Figure 4B and data not shown). Using biotinylated Epo, we could demonstrate that inhibition of PKC and PI3K does not affect EpoR membrane expression (see experimental procedures; data not shown).
This prompted us to investigate whether inhibition of PI3K and PKC would affect JAK2 kinase activity per se or the association of JAK2 with the EpoR. Primary human erythroid progenitors and murine erythroid cells (LK I/11) were preincubated with specific inhibitors: the JAK2 inhibitor AG490 (50µM), the PKC-inhibitor Gö6976 (500nM) and the PI3K-inhibitor LY294002 (30µM). Subsequently, cells were stimulated with Epo, and JAK2 was immunoprecipitated from cell lysates. One half of the immune complex was tested on Western blot to verify that equal amounts of JAK2 were precipitated (data not shown), the other half was used to assess in vitro kinase activity. Inhibitors were either used to by guest on http://www.jbc.org/ Downloaded from preincubate the cells (in vivo treatment), or they were added during the JAK2 in vitro kinase assay, using lysates of Epo-stimulated, non-pretreated cells (in vitro treatment). In contrast to JAK2 tyrosine phosphorylation in vivo (measured by phosphotyrosine antibodies), which was strongly inducible by Epo (Fig 4) , JAK2 in vitro autophosphorylation was maximal in the presence or absence of Epo. Both in vivo and in vitro addition of AG490 inhibited JAK2 kinase activity. We assume that AG490 added in vivo remains associated with JAK2 during the immunoprecipitations. Significantly, the PKC-and PI3K-inhibitors had no effect on the in vitro kinase activity of JAK2, irrespective whether they were added in vivo or in vitro ( Figure   7A ). The same lysates were examined for Epo-induced tyrosine phosphorylation of the EpoR and JAK2 and for tyrosine phosphorylated proteins on a Western blot to verify that the inhibitors had been effective in these experiments (data conform those shown in figure 4B ).
The experimental results indicate that PKC-and PI3K-inhibitors prevent Epo-induced phosphorylation of the EpoR, but that they do not affect JAK2 kinase activity per se, as determined in in vitro kinase assays.
To analyze, whether PKC-inhibitors interfere with the association of the EpoR and JAK2, we determined JAK2 kinase activity co-immunoprecipitating with the EpoR from lysates of cells treated with the various inhibitors as described above. Immunocomplexes containing the EpoR were subjected to an in vitro kinase assay, which resulted in incorporation of radioactively labeled phosphate mainly into a 130 kD protein co-migrating with JAK2.
Addition of AG490 in vitro inhibited phosphorylation of this protein ( Figure 7B ). Together these results indicate that active JAK2 kinase is co-immunoprecipitated with the EpoR.
Preincubation of the cells with AG490 also inhibited phosphorylation of JAK2. Since, it is very well possible that AG490 remains bound to JAK2 (Figure 7A ), we can not conclude that AG490 inhibits association of JAK2 with the EpoR. Significantly, the PKC-and PI3K-inhibitors had no effect on the in vitro kinase activity of JAK2 co-immunoprecipitating with the EpoR, suggesting that they do not interfere with the association of JAK2 with the EpoR (Figure 7B ). In parallel experiments, the tyrosine kinases LYN, SYK and TEC were immunoprecipitated and their kinase activity was determined in the presence or absence of inhibitors. AG490 did not inhibit the in vitro kinase activity of these kinases (data not shown), confirming the in vitro specificity of AG490 with regard to tyrosine kinases as described previously (51) . Stable expression of mutated proteins may be incompatible with expansion of erythroid progenitors or it could affect the formation of protein-complexes such that the effect extends the function of the protein under study. However, the risk of inhibitors is their potential aspecific effects. Using PKC-inhibitors it also needs to be considered that some compounds only block a subset of PKC-isotypes efficiently. Depending on the cell type, distinct isotypes may have the same function. As a result, certain inhibitors can be active in some cell types, but not in others (56, 57) . To eliminate all these risks we used inhibitors that block the ATPbinding site (GF), the catalytic site (chelerythrine) or the regulatory domain (CalC), plus an inhibitor specific for Ca ++ -dependent PKC-isotypes and an inhibitor that depletes PKC from the cell by proteolysis (PMA >4hrs). These inhibitors yielded consistent results at relevant concentrations. Moreover, activation of PKC by two distinct activators (Bryostatin and PMA) yielded opposite results. Therefore, we judge the obtained results to be reliable. KIT. In contrast, to deplete the membrane from 3-phosphoinositides, PI3K activity needs to be suppressed more widely and some PI3K family members are less sensitive to LY294002 (60, 61) .
PKC and PI3K act in concert to control EpoR signaling
PKC may act upstream of the EpoR.
Inhibition of PKC has been reported to interfere with Epo-induced phosphorylation of RAF and ERK (25) 
Potential targets of PKC in the EpoR signaling complex
Intriguingly, PKC is required for Epo-induced phosphorylation of the EpoR, while it affects JAK2 phosphorylation to a much lesser extent. This suggests that JAK2 has to interact with Alternatively, it could be the interacting proteins that require phosphorylation to interact.
Interesting candidate targets in this respect are TEC-family members, recruited to the membrane by their PH-domain, able to associate with PKC (64) 
Effect of PKC on erythroid proliferation and differentiation
We showed that active PKC is required for EpoR signaling, while it was shown to attenuate c-Kit signaling (30) . Renewal divisions of primary erythroblasts require low Epo-levels while high Epo-levels are required for terminal erythroid differentiation. Thus, PKC could control a balance between proliferation and differentiation of erythroid cells. Decreased PKC-activity is expected to result in reduced EpoR-, maximal cKit-signaling, while activation of PKC would result in maximal EpoR-, reduced cKit-signaling. In accordance, we observed that inhibition of PKC allowed 'renewal divisions' in the presence of Epo, SCF and Dex, while Epo-induced terminal differentiation was completely inhibited. In the cultures used the immature cells lack
GlycophorinA expression, while induction of differentiation is accompanied by increased GlycophorinA expression. Thus, our data comply with recently published data demonstrating the requirement of PKCα for the development of CD34 + -progenitors into GPA-positive erythroid cells (20) . In this study, however, no discrimination between expansion and differentiation could be made. PKC isotypes were assessed in primary erythroid progenitors grown from human bone marrow , using isotype specific antibodies on a Western blot. As a control, the antibodies were pretreated with the peptides against which they were raised, which abrogated the specific signal. 
